Indaptus Therapeutics (INDP) reported Thursday new data from an ongoing phase 1 trial of Decoy20, which validated Decoy20's ability to modulate a patient's immune system in a "controlled and potentially meaningful way."
The biotechnology company said weekly treatment with Decoy20 led to broad immune cell trafficking that is a key pharmacodynamic marker, which is "critical for successful anti-tumor therapy," Indaptus Chief Scientific Officer Michael Newman said.
INDP shares were 3% lower in recent premarket activity.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。